Belgian Biotech Stock News

Wondering if KBC Ancora is still a smart buy after its big run up, or if you are turning up late to the party? This breakdown will help you decide whether the current price really makes sense. The share price has climbed an impressive 51.9% over the last year and 169.6% over five years, even after a recent 2.1% slip over the past week and a 2.9% gain in the last month. Much of this move has been driven by shifting sentiment toward European financials and holding companies that give leveraged...

As European markets show resilience with the STOXX Europe 600 Index rising by 2.35%, investors are keenly observing inflation trends and fiscal policies that could shape economic stability in the region. In this context, growth companies with high insider ownership can be particularly appealing, as they often signal strong confidence from those closest to the business and may offer potential for robust performance amid evolving market conditions.

Proximus PLC ( EBR:PROX ) is about to trade ex-dividend in the next 2 days. The ex-dividend date is usually set to be...

ageas SA/NV ( EBR:AGS ) is about to trade ex-dividend in the next three days. Typically, the ex-dividend date is two...

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

When close to half the companies in Belgium have price-to-earnings ratios (or "P/E's") below 14x, you may consider...

Curious if Umicore is a hidden bargain or just along for the ride? You are in the right place to get the facts on its current price versus long-term value. The stock has been anything but boring this year, jumping 40.0% year-to-date and 45.1% over the last 12 months. This comes despite some recent short-term dips of -4.1% in the past week and -15.8% over the last month. These swings follow headlines about Umicore’s partnerships to secure raw materials for battery production and ongoing...

As European markets navigate the challenges posed by inflated AI stock valuations and shifting interest rate expectations, investors are increasingly focused on identifying growth opportunities that can withstand such volatility. In this context, companies with high insider ownership often signal strong alignment between management and shareholder interests, making them potentially attractive in today's uncertain economic landscape.

Wondering if Azelis Group might be an overlooked value pick or if caution is justified? You are not alone. There is a lot to unpack on this stock right now. The share price has taken a notable dive recently, falling 4.3% in the last week and tumbling over 14% in the past month. This brings the year-to-date performance down by a steep 51.3%. These sharp moves are drawing attention, especially since the chemical distributor sector has faced ongoing volatility amidst shifting market conditions...

Agfa-Gevaert (ENXTBR:AGFB) just released its third quarter and nine-month 2025 earnings results. The report shows that sales have dipped and net losses have widened this quarter compared to the same period last year. See our latest analysis for Agfa-Gevaert. Agfa-Gevaert’s latest trading has been turbulent, with the share price dropping sharply by 20% over the past week and now sitting at $0.625. Looking at the bigger picture, momentum is clearly weak, as the 1-year total shareholder return...

Viohalco S.A. ( EBR:VIO ) shares have continued their recent momentum with a 31% gain in the last month alone. The last...

When close to half the companies in Belgium have price-to-earnings ratios (or "P/E's") above 15x, you may consider DEME...

Agfa-Gevaert NV recently reported its third quarter 2025 earnings, revealing sales of €257 million and a net loss of €19 million, both down compared to the same period last year. Although the company's nine-month net loss improved versus the previous year, the quarterly results point to continued operational headwinds affecting Agfa-Gevaert's performance. We'll explore how the combination of declining quarterly sales and a widening net loss is shaping Agfa-Gevaert's investment narrative. AI...

Earlier this month, Barco announced the expansion of its strategic ClickShare partnerships with Sennheiser, Logitech, and Huddly, aiming to deliver integrated, high-performance meeting room solutions through certified room system bundles built around the new ClickShare Hub. This collaboration leverages advanced audio and video technologies to strengthen Barco's position in the wireless BYOD and meeting room systems market, facilitating broader adoption of its solutions in diverse meeting...

NV Bekaert (ENXTBR:BEKB) just announced a partnership with EMSTEEL to develop sustainable steel products and solutions using UAE-made steel. The collaboration covers technical cooperation and aims to expand offerings across Gulf markets. See our latest analysis for NV Bekaert. Bekaert’s recent partnership news comes after a steady period for its stock, with year-to-date share price gains of 3.57% and a solid 12.82% total shareholder return over the past year. Despite some short-term...

Cenergy Holdings reported third-quarter and nine-month 2025 results, delivering sales of €524.27 million and €1.55 billion, and net income of €52.43 million and €147.69 million, respectively, both up from the prior year. Sales and net income growth outpaced the previous year's comparable periods, suggesting the company's operations benefited from strong demand and improved profitability. We'll take a closer look at how Cenergy Holdings' strong revenue and earnings growth this quarter informs...

While D'Ieteren Group SA ( EBR:DIE ) shareholders are probably generally happy, the stock hasn't had particularly good...

Belgian holding company GBL recently sold half its stake in Umicore through an accelerated bookbuild, reducing its ownership from 16% to 8% and committing to a 90-day lock-up on its remaining shares. This transaction reflects GBL’s broader plan to streamline its portfolio towards private assets and follows a period of recovery for Umicore’s share price. We'll assess how GBL's sizable stake reduction impacts Umicore’s investment outlook and potential capital structure considerations going...

Azelis Group (ENXTBR:AZE) shares have recently caught the attention of market watchers, with moves in the stock price reflecting a broader pattern in the specialty chemicals sector. Trading activity suggests investors are weighing up the company’s most recent business fundamentals. See our latest analysis for Azelis Group. Azelis Group’s 1-year total shareholder return of -48.71% reflects a tough stretch for the business, with momentum clearly fading as the stock’s YTD share price return sits...

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Key Insights The projected fair value for Melexis is €54.64 based on 2 Stage Free Cash Flow to Equity With €55.65 share...

KBC Group NV reported third quarter and nine-month earnings for the period ended September 30, 2025, with net income rising to €1.00 billion for the quarter and €2.57 billion for the nine months, both higher than the same periods last year. The company's earnings per share from continuing operations also increased over both periods, reflecting improved profitability and operational performance. We'll assess how the jump in net income and earnings per share informs KBC Group's ongoing...

Noveon Magnetics and Solvay recently announced a multi-year supply agreement for light and heavy rare earth oxides, with Solvay providing Neodymium-Praseodymium, Dysprosium, and Terbium oxides, sourced partly from recycled materials, to support Noveon's production of permanent magnets starting in 2026. This collaboration advances a more resilient and sustainable domestic supply chain for rare earth magnets amid ongoing global supply risks and growing demand. The agreement enhances Solvay's...

argenx SE recently received Health Canada approval for VYVGART SC as a monotherapy for adult patients with active chronic inflammatory demyelinating polyneuropathy (CIDP), making it the first innovative CIDP treatment option in Canada in over 30 years and the first FcRn blocker approved for this use. The once-weekly, subcutaneous self-administration of VYVGART SC presents a new level of flexibility and convenience for patients while potentially reducing demand for human-derived blood...